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INTRODUCTION
Continuous positive airway pressure treatment (PAP) is gener-
ally considered to be the best treatment for obstructive sleep
apnea (OSA) (1, 2). Its efficacy depends on the patient’s willing-
ness to use the device and wear the nasal mask during sleep. Co-
mpliance is the main determinant for success in patients who are
prescribed PAP therapy. The American Thoracic Society has indi-
cated that the overall compliance rates approach 50% at best (1),
and it has been reported that most patients who discontinue PAP
therapy do so within the first few months. Rolfe et al. (3) report-
ed that 78% of the treatment interruptions took place within two
months and 90% took place within four months of the initiation
of treatment.
The influence of the upper airway on PAP therapy has recent-
ly been studied. We previously reported a correlation between
the pressure level of PAP therapy and upper airway narrowing
with the intolerance of patients for a high expiratory pressure
from the machine (4). Patients frequently complain of this dis-
Objectives. There is still debate concerning the reason for the high initial failure rate of positive airway pressure (PAP)
treatment. The objective of this study is to investigate the factors of the initial adherence to PAP, with an empha-
sis on the role of upper airway narrowing.
Methods. The patients were divided into two groups according to the continuation of therapy within the first three months
of treatment. The demographic and polysomnographic findings, the minimal nasal cross sectional area (MCA), the
degree of palatine tonsilar hypertrophy (PTH) and the modified Mallampati grade of the oropharynx inlet (Orophx)
were compared between the study groups.
Results. Among 36 patients, 23 continued the auto-adjusting positive airway pressure (APAP) therapy (the adherent group)
and 13 discontinued APAP within three months (the non-adherent group). The apnea-hypopnea index (AHI) was
significantly higher in the adherent group than in the non-adherent group (P<0.001). The AHI distributions of the
two groups are extremely different. Thirteen of the 23 patients in the adherent group had an AHI of more than
60/hr, while none of the patients in the non-adherent group had an AHI of more than 60/hr. In the patients with
an AHI from 15 to 60/hr, the MCA at the wide side of the nasal cavity and the sum of the MCAs of both sides
were significantly larger in the adherent group than those values in the non-adherent group (P=0.004). The PTH
and the Orophx were not significantly different between the two groups.
Conclusion. AHI is a definite significant factor of adherence to APAP therapy. The dimension of the nasal cavity has an
influence on initial APAP adherence in the patients who have a not too high level of AHI.
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giura et al. (5) reported that nasal resistance has a significant effect
on the initial acceptance of PAP therapy. The aim of this study
was to investigate whether upper airway narrowing can affect
the adherence of patients to PAP therapy.
MATERIALS AND METHODS
The patients who were diagnosed to have OSAS by polysomnog-
raphy and who had started auto-adjusting positive airway pres-
sure (APAP) treatment from March 2005 to March 2006 were
enrolled in this study. The patients were referred to our depart-
ment with complaints of snoring and sleep apnea. Those patients
excluded from the study had undergone prior surgery for OSAS
or had reduced cardiac function or chronic obstructive pul-
monary disease at the time of the study. The study was approved
by the institutional ethics committee, and informed written con-
sents were obtained from all the patients included in this study.
Polysomnography (PSG) was performed before starting ther-
apy and only 36 patients who had apnea-hypopnea index (AHI)
higher than 15/hr and agreed to start APAP treatment were in-
cluded in this study. An ENT otolaryngologist evaluated the upper
airway prior to the start of the initial sleep study. The patients
were regularly followed at three- to four-week intervals. In this
study, adherence was defined by continuation of therapy for more
than three months. The patients were divided into two groups,
that is, the adherent and non-adherent groups.
Evaluation of the pharyngeal inlet
The degree of palatine tonsilar hypertrophy (PTH) was graded
using the Friedman’s classification as follows: grade 0, surgically
removed tonsils; grade I, tonsils within the pillars; grade II, ton-
sils extending to the pillars; grade III, tonsils beyond the pillars
but not to the midline; and grade IV, tonsils extending to the mid-
line (also known as kissing tonsils) (6). The shape of the oropha-
ryngeal inlet (Orophx) was evaluated with mouth open and with-
out protrusion of the tongue using a modification of Mallampati’s
technique and was graded as follows: grade I, tonsils, pillars and
soft palate clearly visible; grade II, the uvula, pillars and upper
pole of the tonsils visible; grade III, only part of the soft palate
visible with the tonsils, pillars and the base of the uvula invisible;
finally, grade IV, only the hard palate visible.
Evaluation of the nasal pathway
Acoustic rhinometric measurement was performed using the
ECCOVISION Acoustic Rhinometer (Model AR-1003; Hood
Laboratories, Pembroke, MA, USA) with the patient in the seat-
ed position. The minimal cross-sectional area (MCA) was mea-
sured, which corresponds to the narrowing at the head of the
inferior turbinate (2 cm from the nasal inlet). We evaluated the
MCA at the narrow and wide sides of the nasal cavity, respec-
tively, and we calculated the summation of both MCAs.
Severity of the OSA and the APAP level
Before starting the APAP therapy, overnight polysomnography
was performed using the Alice3 (Healthdyne Technologies, Ma-
rietta, GA, USA) recorder to monitor the electroencephalogram
(C3-A2, C4-A1), the left and right electro-oculograms, the elec-
trocardiogram, the chin and anterior tibialis electromyograms,
the abdominal and thoracic movements via inductive plethys-
mography and the nasal oral airflow and the oxygen saturation
via pulse oxymetry (SpO2). Apnea was defined as the cessation
of breathing for at least 10 sec, and hypopnea was defined as a
decrease in airflow of at least 50% or a decrease in the SpO2 of
at least 4%, as compared with the baseline. The AHI was calcu-
lated, and we obtained other polysomnographic data such as the
apnea index (AI) and the lowest O2 saturation. The AHI, the
lowest O2 desaturation (minO2) and the Epworth sleepiness scale
(ESS) were determined and compared between the two groups.
We prescribed an APAP device that could adjust the PAP level
on a minute-by-minute basis within certain ranges around the
titration pressure. At every visit after starting the therapy, we
checked the data of the patients’ use of the device, which had
been recorded in the APAP device. The effective pressure levels
that eliminated 95% of the apnea and hypopnea events (effPr)
were also compared between the two groups.
Statistical analysis
The Mann-Whitney’s U test was performed with SPSS ver. 10.0
(SPSS Inc., Chicago, IL, USA) to compare the variables of the
two groups. The gender ratios of the two groups were compared
with chi-square test. The significance level was set at P<0.05 in
all the analyses.
RESULTS
Among the 36 patients, 23 continued the APAP therapy (the
adherent group) and 13 discontinued it (the non-adherent group)
within three months. The mean hours of use a day was 5 hr and
52 min in the adherent group and 4 hr and 10 min in the non-
adherent group (Table 1). In the non-adherent group, 69.2% of
the patients discontinued therapy within one month and 92.3%
discontinued therapy within two months (Table 1).
There was no significant difference in the patients’ age and the
gender distribution. The severity of the OSA was an important
factor for determining the adherence to APAP therapy. The mean
AHI was 63.32 in the adherent group and it was significantly hi-
gher than the mean AHI (28.72) in the non-adherent group (P<
0.001). The MinO2 was significantly lower in the adherent group
(P=0.032). The ESS was higher in the adherent group than that
in the non-adherent group, but this was without statistical signifi-
cance. There was no significant difference in the effPr, the MCAs,
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the two groups (Table 2).
The AHI was a factor associated with compliance with APAP
therapy. However, the difference between the AHI distribu-
tions between the two groups was very large in this study.
There was no patient with an AHI more than 60 in the non-
adherent group (Table 3). Therefore, we limited the subjects to
those with an AHI lower than 60/hr (range, 15 to 60/hr). For
the 23 patients with an AHI 15 to 60/hr, the mean MCA at the
wide side of the nasal cavity was 1.83 cm
2 in the adherent group,
which was significantly greater than that (1.12 cm
2) in the non-
adherent group (P=0.004), while the MCAs at the narrow sides
of the two groups were not significantly different. The sum of
both MCAs was significantly greater in the adherent group (2.82
cm
2) than that in the non-adherent group (2.07 cm
2; P=0.028).
There was no significant difference in the age and gender distri-
bution, the AHI, the ESS, the MCA at the narrow side, the APAP
level (effPr), the grade of tonsilar hypertrophy (PTH), the grade
of oropharynx inlet (Orophx) and the BMI between the two gr-
oups (Table 4).
DISCUSSION
Compliance with PAP therapy is reported to be 50% at best.
However, no specific factor associated with PAP compliance has
been identified. Generally, the severity of OSA is considered to
be the most important factor for predicting compliance. In a pro-
spective cohort study of 163 patients, Pelletier-Fleury et al. (7)
found that the female gender, a low BMI, a low AHI (<30/hr), a
low ESS score and a high CPAP level (>12 cm H2O) were pre-
dictive factors for non-compliance (7). McArdle et al. (8), in a
So YK et al.: Initial Adherence to Positive Airway Pressure Therapy 183
Adherent group Non-adherent group
Table 1. Data of the auto-adjusting positive airway pressure (APAP)
use by the patients in the adherent group and the non-adherent
group. The mean hours of use a day was significantly longer in the
adherent group than that in the non-adherent group. Of the patients
who quit APAP therapy, 69.2% did so within a month and 92.3%
did so within 2 months
Mean hours of use (/day) 5 hr 52 min 4 hr 10 min
Mean days of use (%) 82.6 59.0
Time of drop-out
<1 month . 9
≥1, <2 months . 3
≥2, <3 months . 1
Adherent group Non-adherent group P-value
Table 2. Analysis of the factors for the auto-adjusting positive airway
pressure adherence
*Values are expressed as means±SD.
AHI: apnea-hypopnea index; ESS: Epworth sleepiness scale; minO2: the
lowest point of O2 desaturation; BMI: body mass index; effPr: effective pres-
sure levels that eliminated 95% of the apnea and the hypopnea events;
nMCA: minimal cross sectional area in the narrow side of the nasal cavity;
wMCA: minimal cross sectional area in the wide side of the nasal cavity;
sum MCA: summation of both MCAs; PTH: grade of the palatine tonsilar
hypertrophy; Orophx: modified Mallampati grade of the oropharynx inlet. 
Age 48.5±9.9 48.5±10.3 0.656
Male:female 21:2 11:2 0.917
AHI (/hr) 63.32±25.17 28.72±11.41 <0.001
ESS 11.32±5.30 9.00±4.58 0.281
minO2 (%) 74.90±9.62 81.42±3.70 0.032
BMI (kg/m
2) 26.09±3.72 26.20±5.77 0.856
effPr (cmH2O) 9.43±2.23 8.97±2.64 0.869
nMCA (cm
2) 0.82±0.35 0.94±0.32 0.233
wMCA (cm
2) 1.37±0.64 1.12±0.23 0.427
sumMCA (cm
2) 2.19±0.92 2.07±0.54 0.825
PTH 1.27±0.70 1.50±0.80 0.394
Orophx 2.42±0.90 2.42±0.79 0.911
Adherent group Non-adherent group P-value
Table 4. Analysis of the factors for auto-adjusting positive airway
pressure adherence in the patients with an AHI from 15 to 60/hr
*Values are expressed as means±SD.
AHI: apnea-hypopnea index; ESS: Epworth sleepiness scale; minO2:  low-
est point of O2 desaturation; BMI: body mass index; effPr: effective pres-
sure levels that eliminated 95% of the apnea and the hypopnea events;
nMCA: minimal cross sectional area in the narrow side of the nasal cavity;
wMCA: minimal cross sectional area in the wide side of the nasal cavity;
sum MCA: summation of both MCAs; PTH: grade of the palatine tonsilar
hypertrophy; Orophx: modified Mallampati grade of the oropharynx inlet.
Age 50.20±11.18 49.92±10.27 0.950
Gender (M:F) 10:0 12:1 0.370
AHI (/hr) 40.75±16.95 28.21±11.41 0.094
ESS 11.40±5.08 9.00±4.08 0.383
minO2 (%) 79.50±5.98 81.41±3.70 0.534
BMI (kg/m
2) 24.23±2.15 26.20±5.77 0.420
effPr (cmH2O) 8.71±1.64 8.97±2.64 0.513
nMCA (cm
2) 0.99±0.35 0.94±0.32 0.841
wMCA (cm
2) 1.83±0.43 1.12±0.23 0.004
sumMCA (cm
2) 2.82±0.64 2.07±0.54 0.028
PTH 1.11±0.33 1.50±0.80 0.215
Orophx 2.14±0.90 2.42±0.79 0.344
AHI (/hr)
Total
15-30 31-45 46-60 61-
Table 3. The distributions of the apnea-hypopnea index (AHI) levels
The AHI distributions of the two groups were extremely different. Over half
of the patients in the adherent group had an AHI more than 60/hr, while all
the patients in the non-adherent group had an AHI less than 60/hr. 
Adherent group 3 3 4 13 23
Non-adherent group 9 2 2 0 13prospective study of 1,211 patients, showed that the ESS score
and the AHI were the significant independent predictors of long-
term use of PAP.
Nasal side effects are believed to account for 30-50% of the
patients who are unable to tolerate PAP (9, 10). Therefore, the
influence of upper airway narrowing on PAP therapy has recent-
ly been studied. First, it has been reported that in patients with
nasal obstruction, the PAP level decreased after surgical proce-
dures for nasal obstruction (such as septoplasty and turbinoplas-
ty) (11, 12). In addition, it was reported that in patients with a
BMI <25, there was no significant correlation between the nasal
cross sectional area and the APAP level, and this was indepen-
dent from nasal surgery (3, 13).
A reduced or lower PAP level is thought to reduce the nasal
discomfort of PAP therapy and to improve the use of PAP. How-
ever, any correlation between the PAP level and PAP compli-
ance has not been clearly identified. Several studies on PAP ther-
apy have not found any correlation between these two parame-
ters (14-17).
Consequently, the correlation between narrowing of the nasal
airway and PAP compliance is uncertain. Sugiura et al. (5) report-
ed that the AHI and the nasal resistance evaluated by rhinoman-
nometry were significant factors for predicting the compliance
with PAP at one month. Furthermore, Morris et al. (17) report-
ed that the nasal cross-sectional area was a significant factor for
PAP compliance after 18 months and that age, gender, the BMI,
the PAP level or the AHI had no influence on compliance. How-
ever, Schechter et al. (18) showed that PAP compliance after one
month was not affected by the nasal cross-sectional area, as eval-
uated by acoustic rhinometry. In this study, age, gender and the
BMI also had no influence; the AHI was the only significant fac-
tor associated with PAP compliance.
These differences between study results might have been ca-
used by the different characteristics of the study population. For
example, in some studies, the AHIs in the study group and the
control group were too variable, while in other studies, the AHIs
of all the patients were in a narrow range and they were almost
the same. Comparison of groups with widely variable AHI dis-
tributions that can have an influence on other factors may be sub-
ject to a confounding bias. In addition, different definitions of co-
mpliance and the length of the follow-up may also contribute to
the conflicting results. Furthermore, the small sizes of the vari-
ous study groups could make the results variable and statistical-
ly insignificant.
In the present study, the AHI was the significant parameter that
was associated with adherence, which was defined as still using
APAP after three months. However, the distributions of the AHIs
in the adherent and non-adherent groups were quite different;
in the adherent group, the mean AHI was 63.32/hr with a stan-
dard deviation of 25.17, while in the non-adherent group, the
mean was 28.72/hr with a standard deviation of 11.41. After li-
miting the AHI level of the two groups, the nasal MCA was found
to be a significant factor for initial adherence to APAP therapy.
Furthermore, in the present study, the MCA results from the
adherent group of the total subjects were different from that of
the limited subjects after excluding the patients with very severe
OSAS (AHI >60/hr). We don’t know the exact cause of this dif-
ference. However, some authors reported that nasal resistance
is associated with AHI (19). Furthermore, the compliance of the
patients with very severe OSAS is very high (4, 20), and the sub-
jective gain from using PAP in this group may conceal the differ-
ence of other variables.
Last, in the present study, we used the term ‘adherence’ that
was defined as still using APAP after the research period. There
is a lack of a standard definition of compliance or adherence with
PAP use in the medical literature. In general, adequate compli-
ance is defined as at least 4 hr of use per night on at least 70%
of the nights, and compliance is a word that is often used inter-
changeably with adherence. We used the term ‘adherence’ acc-
ording to the suggestion of Dr. Collard, who defined adherence
as pursuing PAP treatment after having been provided with a
treatment apparatus (21).
AHI is a significant factor of APAP adherence and this finding
is consistent with that of many previous studies. In addition, the
dimension of the nasal cavity hasan influence on initial APAP
adherence in the patients with a limited range of the AHI, that
is, not too high or not too low.
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